Tokiwa S, et al. - This study was initiated in order to affirm the compatibility of degarelix treatment with diabetes and any specific causal correlations of degarelix injections with increased blood clotting and antithrombotic therapy requirements. It was deduced that preexisting diabetes and antithrombotic therapy did not serve as crucial factors for the discontinuation of degarelix treatment in patients with prostate cancer.